Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Discussion: In the present study, 7 patients harbored the rtL180 M, rtS202G, and rtM204I/V substitutions at a frequency of >1% at baseline, 5 of these patients belonged to the PVR group, and the other 2 belonged to the CVR group.
Discussion: One study reported that the most commonly detected mutations were M204 V/I, M250 V/I, A181T/V, and N236T.
Discussion: UDPS indicated that NAr mutations were pre-existent at low percentages (ranging from 0.1% to 6.7%) at baseline, including rtV173A/M, rt
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Abstract: The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04).
Introduction: Regarding HBV mutations, the use of 3TC alone has been shown to be strongly associated with consistently high HBV viremia due to the rapid emergence of HBV mutants carrying the M204I/V mutation conferring resistance to 3TC/FTC.
Method: Using the Mutation Reporter Tool software (http://hvdr.bioinf.wits.ac.za/mrt/), HBV resistance-associated mutations (RAMs) in the pol gene represented by
Result: Regarding RAMs, the mutation M204V/I, associated with the compensatory mutation L180M, was significantly more common in genotype HBV/A (9/19, 47.4%) than in genotype HBV/E (0/9, 0%) (Yate's corrected chi2, P = .04) (Fig 6, Table 2).
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Result: Although all 12 patients experienced viral breakthrough during the treatment with LAM, low rates of drug resistance-associated mutations were observed at week 0 prior to the treatment, with the exception of patient D, who exhibited a rate of 94.03 for M204I, and patient G, who exhibited a rate of 97.59 for A181V.
Result: Furthermore, the increased mutation rate of rt180 or rt80 was accompanied by the occurrence of the high mutation rate of M204I during the virological breakthrough.
Result: Notably, the mutation rate of rtM204I/V was markedly increased at the time of virological breakthrough in eight patients, and this was accompanied by an increased mutation rate of rt
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
PMID: 26136470
2016
The Journal of infectious diseases
Abstract: The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%).
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
GENOMIC ANALYSIS OF HEPATITIS B VIRUS STRAINS INFECTING ROMANIAN PATIENTS.
PMID: 26727850
2015
Roumanian archives of microbiology and immunology
Abstract: An HBV isolate displaying a lamivudine complex resistance pattern, rtM204I in conjunction with rtL180M and rtA200V, was found in a lamivudine naive patient.
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Discussion: Additionally, once the rtM204I mutant prevailed over the rtA181T and wild-type viruses, we observed that VB developed quickly and that rtM204I predominated among the viral quasispecies, supporting the argument that the rtM204I mutant may have greater fitness than the rtA181T mutant under LdT treatment.
Discussion: Although we could not completely rule out the possibility that rtA181T and rtM204I simultaneously exist in the same genome due to the limited sequencing coverage in this study, o
Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection.
Result: There were no drug resistant mutations (lamivudine-resistant pattern: rtM204V/I, rtL180M, rtV173L, adefovir-resistant pattern: rtA181V/T, tenofovir-resistant pattern: rtA194T and entecavir-resistant pattern: rtL180M, rtS202G, rtM204V) detectable in acute patients belonging to our study population.
[Variability of Reverse Transcriptase Gene and S Gene in Lamivudine-treated Chronic Hepatitis B Patients].
HBV mutation literature information.
PMID: 
2016
Medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT